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Mesenchymal stem or stromal cells (MSC) are a hetero-
geneous population of cells (1), readily isolated from bone
marrow. In addition to potential for tissue repair, MSC
possess potent anti-proliferative and anti-inflammatory effects
(2, 3) which support their therapeutic use for immune-
mediated diseases. Preclinical models of autoimmune/inflam-
matory conditions have demonstrated a beneficial role for
MSC in graft tolerance (4), rheumatoid arthritis (5), and
multiple sclerosis (6). Protective roles have also been described
in models of acute lung injury, including pulmonary fibrosis
(7) and more recently allergic rhinitis (8). However, the precise
mechanism by which MSC mediate protection is less clear.
Allergic asthma is an inflammatory disease of the airways,
driven in part by Th2- cell induction, eosinophil and mast
cell activation and mediator release (9), to establish an
inflammatory response combined with profound airway
remodeling. Current therapies for allergic asthma include the
use of glucocorticoids, however, even long-term pharmaco-
therapies do not re-program the underlying immune devia-
tion which drives pathology (10). There is an unmet need to
develop strategies to reverse immunologic reactivity and
chronic airway inflammation.
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Abstract
Background: Adult bone marrow-derived mesenchymal stem cells (MSC) possess
potent immune modulatory effects which support their possible use as a therapy for
immune-mediated disease. MSC induce regulatory T cells (Treg) in vitro although
the in vivo relevance of this is not clear.
Objective: This study addressed the hypothesis that adult bone marrow derived-
MSC would prevent the pathology associated with allergen-driven airway inflamma-
tion, and sought to define the effector mechanism.
Methods: The influence of allogeneic MSC was examined in a model system where
Treg induction is essential to prevent pathology. This was tested using a combination
of a model of ovalbumin-driven inflammation with allogeneic MSC cell therapy.
Results: Systemic administration of allogeneic MSC protected the airways from
allergen-induced pathology, reducing airway inflammation and allergen-specific IgE.
MSC were not globally suppressive but induced CD4+FoxP3+ T cells and modu-
lated cell-mediated responses at a local and systemic level, decreasing IL-4 but
increasing IL-10 in bronchial fluid and from allergen re-stimulated splenocytes.
Moderate dose cyclophosphamide protocols were used to differentially ablate Treg
responses; under these conditions the major beneficial effect of MSC therapy was
lost, suggesting induction of Treg as the key mechanism of action by MSC in this
model. In spite of the elimination of Treg, a significant reduction in airway eosino-
philia persisted in those treated with MSC.
Conclusion: These data demonstrate that MSC induce Treg in vivo and reduce
allergen-driven pathology. Multiple Treg dependent and independent mechanisms of
therapeutic action are employed by MSC.
Abbreviations
BALF, bronchoalveolar lavage fluid; CY, cyclophosphamide; GVHD,
graft-versus-host-disease; H&E, haematoxylin and eosin; MSC,
mesenchymal stem cells; OVA, ovalbumin; PAS, periodic acid
Schiff; PBS, phosphate buffered saline; PFA, paraformaldehyde;
PGE-2, prostaglandin E2; Treg, regulatory T cells; TGF-b,
transforming growth factor-B.
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Recent advances in immunological understanding have
re-evaluated the role of suppression and demonstrated that
pathogenic T cells can be actively countered by regulatory
CD4+CD25+FoxP3+ T cells (Treg) in murine models (11).
In these situations the development of allergic airway inflam-
mation is due to inadequate, defective or overwhelmed Treg
responses. These models provide powerful tools to study the
influence of the suppressive or trophic function of MSC. If
MSC induction of CD4+CD25+ FoxP3+ cells in vitro (12,
13) is mirrored in vivo, then the ovalbumin (OVA) sensitiza-
tion model offers a means to test the biological significance
of MSC as cell therapeutic inhibitors of allergic airway
pathology.
This study addressed the hypothesis that adult bone mar-
row derived-MSC would prevent the pathology associated
with allergen-driven airway inflammation, and sought to
define the effector mechanism. Adult bone marrow derived
allogeneic MSC actively prevented the induction of allergen-
driven pathology in a murine model via induction of Treg
suggesting a novel cell therapy for allergic human disease.
Materials and methods
Animals
Allergen sensitization was as previously described (14)
using 8- to 12-week old, female BALB/cOlaHsd (H-2d) mice
(Harlan, Oxon, UK), whereas FVB/NHanHsd (H-2q) male
mice were the source of allogeneic MSC. Mice were main-
tained according to the regulations of the Irish Department
of Health, and the institutional research ethics committee.
Mice were sensitized by intra-peritoneal injection of 100 lg/
ml ovalbumin (OVA) emulsified in aluminum hydroxide
(AlumImjectTM) (Pierce, IL, USA) on days 0, 7 and 14. Mice
were challenged intra-nasally with OVA (50 lg/ml) or sterile
PBS (sham) on days 14, 25, 26 and 27 (Fig. 1A).
Isolation and culture of bone marrow derived mesenchymal
stem cells
Bone marrow from of FV/BN mice was resuspended in
Mesencult Basal Medium, supplemented with 10% (v/v) Mes-
encult supplement (Stem Cell Technologies, Vancouver, Can-
ada). Cells were maintained as previously described (15), and
used between passages 4 and 9 with rigorous purification and
quality control to ensure purity as previously described (15).
All MSC used were capable of differentiation to the three
major mesenchymal lineages (13), and were MHC class I+,
Sca-1+, CD44low, CD106low, MHC-II), CD11b), CD11c),
CD34), CD45) and CD117). For paraformaldehyde (PFA)-
fixed MSC, cells were pelleted and resuspended in 50 ml PFA
(0.5% in PBS) for 20 min at room temperature, before exten-
sive washing and use.
MSC therapy
Allogeneic H-2q MSC (or fixed control cells) were washed
twice with PBS and resuspended at 5 · 106 cells/ml. A preli-
minary investigation was carried out to ascertain whether
MSC-induced expansion of Treg was dose-dependent and
determine the optimum dose. 100 ll of MSC at 5 · 106,
5 · 105 or 5 · 104 cells/ml were administered i.v. and the
expression of FoxP3 by CD4+ T cells was quantified by
flow cytometry 0, 4, 8 and 12 days following treatment (Fig.
S1). Treg induction reflected MSC dose and was greatest in
mice receiving 0.5 · 106 cells/mouse (Fig. S1); therefore, sub-
sequent experiments utilized this dose. 0.5 · 106 MSC, fixed
MSC or PBS were delivered via tail (100 ll, i.v.) on days 7
and 14 to H-2d mice (n = 8) as follows: (i) sham sensitized-
PBS alone; (ii) OVA-sensitized mice-PBS; (iii) OVA-sensi-
tized mice-MSC; (iv) OVA-sensitized mice + PFA-fixed
MSC; (v) control PBS sham sensitized mice infused with
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Figure 1 Study sesign. (A) OVA sensitization, (B) CY depletion of Treg. CY (150 mg/kg) was delivered via i.p. injection on day 8, 12 and 15.
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MSC; (vi) control sham PBS-sensitized with PFA-fixed MSC
(Fig. 1A). MSC locating to the airways within 24 h as
previously documented (16) and data not shown. At
28 days, bronchoalveolar lavage fluid, and histopathological
studies were performed, serum collected and splenocytes
re-stimulated in vitro (14). All experiments were performed
at least twice.
Histopathology and airway physiology
At 28 days BALF was collected (14) and differential cell
counts performed as described (14). Nonlavaged lungs were
fixed, sectioned and stained with hematoxylin/eosin (H&E), or
combined Discombes/Alcian blue/ periodic acid-Schiff (PAS)
stain (14). Pathology was scored using a semi-quantitative
scoring system as mild, moderate or severe and shown for
convenience in Supporting information (Fig. S2). Lung func-
tion was assessed by unrestrained plethysmography and
expressed as the surrogate index of enhanced pause (PenH)
as previously described (14). This approach has limitations
and was used as supporting rather than a definitive indicator
of airway hyper-responsiveness.
Measurement of cytokines and antibody response
IL-4, IL-10 and IL-13 from BALF or antigen re-stimulated
or control splenocyte supernatants were analyzed by flow
cytometry (Becton-Dickinson, New Jersey, USA), using
Cytometric Bead Array Flex Sets (BD Biosciences, Franklin
Lakes, NJ, USA) according to manufacturer’s instructions.
Standard curves and raw data were generated for each cyto-
kine using FCAP Array v1.0.1 software (BD Biosciences).
OVA-specific serum IgE was measured by ELISA as previ-
ously optimized (17).
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Figure 2 Representative morphological changes in bronchiolar
transverse sections of lungs and BAL composition at day 28 from (A
& E) Nonsensitized, (B & F) OVA-sensitized, (C & G) OVA-sensitized,
MSC treated, (D & H) OVA-sensitized, PFA-fixed MSC treated.
Airway inflammation was detected using H&E (A–D) (magnifica-
tion · 100) and combined Discombes/Alcian blue/PAS (E–H) staining
(magnification · 400). p and h indicate perivascular inflammation
and bronchiolar epithelial hypertrophy, respectively. g and m
indicate goblet cell hyperplasia and mucus secretion, respectively.
Negative controls were sham infected/sensitized with saline. The
data are representative of three experiments; in each case, at least
five animals were assessed. Results are expressed as mean ± SEM
of cell number (*P < 0.05, **P < 0.01).
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Treg depletion and assessment
In Treg studies, mice were sensitized with OVA on day 0, 7
and 14, and MSC delivered on days 7 and 14. An estab-
lished model of pharmacological Treg depletion was
employed (18). Mice received 3 low doses of 150 mg/kg
cyclophosphamide (CY) (Sigma) intraperitoneally on day 8,
12 and 15 (Fig. 1B). On day 19, splenocytes and lung leuko-
cytes were prepared from representative animals. Single cell
suspensions were prepared by dissociating tissue with colla-
genase D (Sigma) and labeled for surface CD4, CD25 and
intracellular FoxP3 as previously described (13). The effec-
tiveness of depletion by dose and time was established in
preliminary experiments and verified by the absence of
CD4+ CD25+FoxP3+ populations in spleen or lungs of test
animals by flow cytometry at the time points selected
(Fig. S3). Remaining mice were challenged with OVA (50 lg
in 30 ll PBS) intranasally on day 25, 26 and day 27 and
assessed as above (Fig. 1B).
Statistical analysis
Values for all measurements were expressed as the mean ±
standard error of the mean (SEM). Statistical analysis was
performed using graphpad prismTM software (GraphPad,
San Diego, CA, USA). Comparison was made using the
Kruskal–Wallis test, or the Mann–Whitney test as appropri-
ate. Significance was denoted by P-value <0.05.
Results
Allogeneic MSC therapy reduces allergen-driven airway
pathology
The influence of MSC cell therapy was examined in a mur-
ine model of allergic pathology. Nonsensitized control mice
exhibited no allergen-driven airway inflammation as
expected (Fig. 2A), whereas OVA-sensitized mice exhibited
typical peribronchial and perivascular inflammation (Fig. 2B).
In contrast, MSC therapy resulted in markedly decreased
pathology, with decreased peribronchial inflammation (Fig. 2
C). Consistent with these data were physiological observa-
tions of a surrogate of airway hyper-responsiveness suggest-
ing that MSC therapy reduced bronchial hyper-reactivity
compared to OVA-sensitized mice (Fig. S3). However MSC
needed to be viable as delivery of PFA-fixed MSC to aller-
gen sensitized mice resulted in more severe pathology when
compared to OVA-sensitized mice, displaying strong perivas-
cular inflammation and bronchiolar epithelial hypertrophy
(Fig. 2D). Thus MSC cell therapy reduces classical allergen-
driven pathology in this model. A consistent feature of
asthma is the production of mucus blockage of the peri-
pheral airways (19). MSC delivery reduced airway mucus,
whereas PFA-fixed MSC exacerbated goblet cell hyper-
plasia and mucus secretion in allergen-sensitized mice
(Fig. 2E–H). Thus live, but not fixed, MSC therapy reduced
multiple characteristic aspects of allergen-driven airway
pathology.
Allogeneic MSC therapy protects against allergen-driven lung
eosinophilia
A cardinal feature of allergen-driven airway inflammation is
the elevated number of inflammatory cells in the lungs, par-
ticularly eosinophils (9). Control mice showed minimal cellu-
larity in bronchoalveolar lavage (Fig. 2), whereas OVA
sensitization resulted in significant infiltration (P < 0.05).
Total cellular infiltration was decreased in OVA-sensitized
mice that received MSC, whereas it remained high in sensi-
tized animals treated with PFA-fixed MSC. BALF from con-
trol mice had few cells, other than macrophages; however
OVA sensitization/challenge resulted in eosinophilic inflam-
mation. Airway eosinophilia was significantly reduced in
OVA sensitized mice following MSC delivery (P < 0.05),
whereas PFA-fixed MSC treatment caused a considerable
increase in airway eosinophilia when compared to OVA
sensitized mice (Fig. 2). The number of macrophages in
BALF was similar to controls. These findings demonstrated
that live allogeneic MSC have wide ranging therapeutic influ-
ence on allergen-driven airway inflammation and in particu-
lar eosinophilic inflammation.
Allogeneic MSC cell therapy induces Treg in vivo and
modulates allergen-specific immunity
IgE induction is a feature of allergen-driven pathologies and
OVA sensitization induces IgE and an allergen-specific
Th2 response (20). The capacity for MSC to influence IgE
induction was examined by measuring OVA-specific IgE in
serum from OVA-sensitized mice in which MSC were used
therapeutically. Allogeneic MSC therapy suppressed the aller-
gen-specific IgE response (Fig. 3), in comparison to mice sen-
Figure 3 OVA-specific IgE in serum elicited in response to OVA
sensitization. Sera were collected on day 28 and OVA-specific
serum IgE levels were measured by ELISA. The data are represen-
tative of three experiments; in each case, at least five animals
were assessed, and each individual assessment was performed
independently in triplicate. Concentrations below 200 pg/ml were
considered negative. Results are expressed as mean antibody
concentrations ± SEM (**P < 0.01, ***P < 0.001).
MSC prevent allergic airway inflammation Kavanagh and Mahon
526 Allergy 66 (2011) 523–531 ª 2010 John Wiley & Sons A/S
sitized to OVA alone (P < 0.05) (Fig. 3). Sensitized mice
that received PFA-fixed MSC showed similar levels of OVA
specific IgE to OVA sensitized mice.
The phenomena described above might be explained by
MSC-mediated global, nonspecific immune suppression or by
MSC interference in immune induction. Therefore, the effect
of allogeneic MSC on T cell mediated immunity was exam-
ined. Particular attention was given to IL-4 and IL-13 induc-
tion as these play well defined roles in allergen-driven
pathology (21). As expected, IL-4 and IL-13 in both BALF
and splenocyte supernatants were significantly higher in the
OVA compared to sham-sensitized mice (Fig. 4). However, a
marked reduction in IL-4 and IL-13, but a significant
increase in IL-10 (Fig. 4) (P < 0.05) was observed in BALF
(Fig. 5B) (P < 0.05). Similarly, when spleen cells were re-
stimulated ex vivo with allergen, IL-10 was increased but a
reduction in IL-13 and IL-4 was observed. This was an
important observation as it shows that the protective effect
of MSC was a result of targeted, specific modulation of local
immunity rather than a global suppression of the immune
response.
The induction of local and systemic IL-10 strongly sug-
gested that MSC were inducing a regulatory T cell popula-
tion. Therefore, the generation and expansion of Treg subsets
was assessed in the lungs and spleens of OVA-sensitized mice,
and mice that received MSC therapy. MSC induced or
expanded a population of regulatory cells; most notably a
CD4+FoxP3+ population was observed in both the lungs
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Figure 4 Spleens and BALF were harvested on day 28. Spleno-
cytes were cultured in the presence of media alone (‘) or OVA
(200 lg/ml) ( ) for 72 h. Cytokine responses from similar cultures
are shown for (A & C) IL-4, (B & D) IL-13 and (C & E) IL-10.
Responses are representative of triplicate experiments, each of
which were determined independently from at least nine mice per
group and are expressed as means ± SEM (*P < 0.05).
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and spleen from sensitized, MSC-treated mice (Fig. 5). A
significant increase in FoxP3 expression (P < 0.05) was
observed in CD4+ T cells from MSC-treated compared to
untreated sensitized mice providing evidence that MSC
induce Treg populations in vivo.
Regulatory T cells are required for MSC mediated inhibition
of allergic airway inflammation
Detection of Treg does not necessarily equate to an essential
function. To investigate whether MSC exerted their immuno-
suppressive function via induction of Treg, these suppressor
cells were depleted and the effect of MSC delivery on airway
pathology was examined. Pharmacological depletion based
on cyclophosphamide (CY) administration has been widely
used to examine the effect of Treg depletion in disease models
(22) as it both impairs functionality and depletes Treg in vivo
(23). Fortunately MSC are ALDH+ (24) and thus, resistant
to CY (25), and showed no impairment in differentiation
capacity to CY during in vitro exposure (data not shown). A
protocol consistent with previous studies (18) was chosen to
allow OVA-specific effector cell induction but which depleted
Treg (Fig. 1B). Contrary to earlier findings, MSC did not con-
fer protection when Treg were depleted. In the absence of
Treg, MSC-treated OVA-sensitized mice displayed significant
cellular infiltration including peribronchial inflammation at
day 28 (Fig. 6) comparable to allergen sensitized mice. Deliv-
ery of MSC in the absence of Treg also resulted in more pro-
nounced levels of mucus production with some airways
showing profound obstruction (Fig. 6). When mice were
depleted of Treg, there was no observable difference in IgE
between those that received MSC and positive controls
(Fig. 6). These data support a model where atopic responses
are moderated in vivo by the suppressive influence of constit-
utive Treg, and more importantly that Treg were required for
the MSC-mediated reduction of pathology and allergen
specific IgE.
MSC cell therapy in Treg-depleted allergen sensitized mice
did not alter the Th2 profile (of IL-4 or -13) in BALF
(Fig. 6) and did not elevate IL-10, in direct contrast to when
Treg were not depleted (Fig. 4). Similarly, MSC therapy in
Treg-depleted mice did not impact on allergen-specific Th2
responses in the spleen. Taken together these data strongly
suggest that the mechanism of beneficial action by MSC in
this model is dependent on the induction of Treg. Thus MSC
modulate allergen specific local and systemic immunity
through a Treg mechanism. A feature of CY treatment in this
model is enhanced pathology and increased airway eosino-
philia (18). Similar findings are reported here (Fig. 6). How-
ever, MSC treatment significantly reduced eosinophilia even
in the absence of Treg (Fig. 6), but did not influence other
indices or improve overall pathology. Together these data
indicate that whilst Treg induction is required to moderate
Th2-driven inflammation, an alternative Treg independent
mechanism might also be employed by MSC.
Discussion
This study demonstrated that adult bone marrow-derived
allogeneic MSC actively prevent the induction of allergen-
driven pathology through a Treg-dependent mechanism.
Systemic administration of MSC protected the airways from
OVA-induced pathology evidenced by reduced lung pathol-
ogy and cellular inflammation in BALF and reduced allergen
specific IgE. MSC were not globally immunosuppressive but
rather immunomodulatory, inducing splenic OVA recall
responses dominated by IL-10, a cytokine also elevated in
BALF by MSC therapy. MSC therapy induced populations
of CD4+FoxP3+ T cells in the lung and spleen. Depletion of
Treg ablated the protective effect of MSC therapy in terms of
the major indices of pathology, and restored class switching
to IgE. Thus Treg are required for the protective effect of
MSC therapy in this model, however MSC continued to
affect eosinophilia indicating that MSC also use Treg-indepen-
dent mechanisms to modulate effector function.
The mechanisms of MSC effector action (and hierarchy)
in vivo are poorly understood. MSC can induce direct repair,
may be cytoprotective, pro-angiogenic, anti-fibrotic or act
through other paracrine effects (6, 7, 16). We have previously
outlined mechanisms by which MSC induce Treg in vitro,
defining roles for cell contact, TGF-b and PGE-2 (13). This
A
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Figure 5 Expression of CD4+FoxP3+ in lymphoid cells isolated
from the lungs (A) and spleen (B) of either OVA-sensitized or OVA-
sensitized MSC-treated mice. Cells were intracellularly stained with
PE-conjugated anti-FoxP3. Responses are representative of dupli-
cate experiments, each of which was determined independently
from at least four mice per group.
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study selected a system where prevention of pathology could
be directly linked to Treg induction in vivo. Increased
CD4+FoxP3+ T cells and elevated IL-10, locally (lung/
BALF) and systemically (spleen) following MSC therapy was
circumstantial evidence for a role for Treg as the mechanism
for MSC-mediated protection in this model. Although the
increase in FoxP3+ Treg was modest, it is quantitatively simi-
lar to recent studies where similar induction was associated
with decreased pathology (26). MSC-mediated immuno-
suppression has been suggested by the expansion of
CD4+FoxP3+ cells in vitro (8, 26). CD4+CD25+FoxP3+
Treg are critical for control of antigen-specific inflammation
[for review (27)] and their recruitment into the airways can
suppress allergic airway inflammation (28). Recently, IL-10
production by Treg was shown to be essential to control
immune responses in the lung (29). The current study
revealed that MSC therapy increased CD4+FoxP3+ T cells
in lung and spleen which was associated with elevated IL-10
supporting the findings of Rubstov with regard to the impor-
tance of Treg/IL-10, but more importantly strongly suggesting
that MSC induction of Treg was not simply an in vitro
phenomenon.
Treg cell induction in vitro or even in vivo by MSC is an
important and interesting finding but its significance depends
on the functional contribution to reduced pathology. Here,
the contribution of Treg, induced by MSC, to exert functional
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Figure 6 Representative morphological changes at 28 days in
bronchiolar transverse sections of lungs from Treg-depleted, sham-
sensitized, Treg-depleted (CY-PBS), OVA-sensitized (CY-OVA) and
Treg-depleted, OVA-sensitized, MSC-treated (CY-OVA MSC). (A) Air-
way inflammation detected using haematoxylin and eosin (H&E)
and combined Discombes/Alcian blue/PAS staining of fixed lung
sections. Original magnification, top panels · 100, bottom pan-
els · 400. (B) OVA-specific IgE in serum elicited in response to
OVA sensitization in Treg depleted mice. (C) Cellular composition of
BAL from Treg depleted mice 24 h after final OVA exposure. (D)
Cytokine profile of BALF elicited by OVA sensitization. All sections
are representative of at least three animals.
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protection was studied using the cyclophosphamide depletion
model. Alternative approaches such as CD25 depletion could
not be used as these would interfere with T cell activation
and Th2 induction and confound interpretation, whereas this
regime differentially depletes functional Treg (30). Using this
model it was shown that Treg induced by allogeneic MSC
therapy were required for the reduction in pathologic score,
mucus secretion and allergen-induced IgE. Thus, this study
goes beyond demonstrating Treg induction in vivo by MSC to
show a biological significance for that process.
Treg depletion ablated most of the beneficial effects of MSC
therapy, indicating the mechanism of protection in this model.
However MSC supported a significant reduction in airway
eosinophilia despite Treg depletion (Fig. 6). This observation
was important for two reasons: firstly it indicated that MSC
could modulate effector cell function by alternative Treg-inde-
pendent mechanisms; secondly as reduced eosinophilia is seen
here whilst the pathology is impaired, it suggests that altered
eosinophilia cannot account for the MSC-mediated effects
seen in Fig. 2, and that the primary mechanism by which
MSC reduce pathology is via Treg induction. We and others
have previously shown that MSC express a variety of immuno-
suppressive cytokines including hepatocyte growth factor
(HGF) at concentrations that can suppress allogeneic
responses in vitro (31). HGF negatively regulates allergic
airway inflammation and hyper-responsiveness (32) via direct
attenuation of eosinophil chemotactic function. The expres-
sion of HGF by MSC (31, 33) and reduced eosinophilia is con-
sistent with such a Treg-independent role, and consistent with
human clinical studies where reduced airway eosinophilia had
little impact on pathology (34). The implication of an alterna-
tive MSC mechanism of action is that MSC therapy may allow
a targeting of complex multi-factorial diseases that involves
both fibrotic and inflammatory processes and Treg-dependent
and independent aspects. Allogeneic MSC possess specific
immunomodulatory properties that target critical pathogenic
features for the development of allergic asthma. Here we
demonstrate the efficacy of MSC based cell therapy in a well
characterized murine model. We also illustrate the mechanism
of action by which protection is mediated as a proof of concept
for MSC based immunotherapy for a broad range of diseases
where chronic inflammation results in pathology.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article at www.wileyonlinelibrary.com:
Figure S1. OVA sensitized mice received 100 ll MSC i.v. of
5 · 103 (open), 5 · 104 (horizontal shading) or 5 · 105 (black
bar) cells/ml. On day 4 or 8 following treatment, lungs were
harvested and digested with collagenase/DNase I for 1 h fol-
lowed by intra/extracellular labelling with PE-conjugated
anti-FoxP3/Cy5-conjugated anti-CD4. Results are expressed
as mean values ± SD obtained from groups of at least three
mice and are representative of two independent experiments.
*P < 0.05; **P < 0.005.
Figure S2. Pathology scoring of H&E-stained lung sections.
Original magnification · 100. Perivascular and peribronchial
inflammation was evaluated as (A) mild, (B) moderate, and
(C) severe. (A) Mild peribronchial inflammation (center) sur-
rounded by clear alveoli and cross-sectioned bronchioles
(bottom left, right). (A) Moderate peribronchial inflammation
surrounding bronchiole (top right, bottom right) and moder-
ate alveolar inflammation. (C) Severe perivascular and peri-
bronchial inflammation with bronchial epithelial hypertrophy
(center, center right).
Figure S3. The effect of CY treatment on CD4+FoxP3+
expression. Mice were given 150 mg/kg of CY intraperitone-
ally at day 0. Spleen cells were isolated followed by intra/
extracellular labeling of anti-FoxP3-PE/anti-CD4-Cy5 then
analyzed by flow cytometry. Results are expressed as mean
values ± SD obtained from groups of at least three mice
and are representative of two independent experiments.
*P < 0.05; **P < 0.005.
Figure S4. Airway responsiveness was assessed on day 37 by
methacholine induced airflow obstruction from conscious
mice using whole-body plethysmography in conjunction with
the BioSystem XA software (Buxco Electronics, USA) as
previously described (14). (A) Nonsensitized (-s-), OVA-
sensitized (- -), OVA-sensitized + MSC-treated (-.-), OVA-
sensitized + PFA-fixed MSC treated (-d-). Results are
expressed as mean enhanced pause (PenH) ± SEM. Where
no error bars are visible, error bars are shorter than the size
of the data point symbol.
Please note: Wiley-Blackwell are not responsible for the con-
tent or functionality of any supporting materials supplied by
the authors. Any queries (other than missing material) should
be directed to the corresponding author for the article.
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